Outcomes Study: Expanding HIV Prevention Access: Linking PrEP Patients to Long-Acting Injectable Lenacapavir Within a Health-System Specialty Pharmacy

Members of our team had the opportunity to present a new poster abstract at NASP inSPIRE 2026, which was held from September 22-25, 2026.

Authors

Sandra Poon, PharmD, AAHIVP; Dan Ge, PharmD; Andrew Wash, PharmD, PhD; Casey Fitzpatrick, PharmD; Ana Lopez Medina, PharmD, PhD; Jessica Mourani, PharmD

Background

• The long-acting injectable lenacapavir (Yeztugo®), approved on July 19, 2025, introduces a biannual option for HIV pre-exposure prophylaxis (PrEP) that may help overcome adherence barriers associated with daily oral regimens.¹

• By requiring only twice-yearly injections, lenacapavir has the potential to substantially reduce the cognitive, behavioral, and logistical demands placed on patients using other forms of PrEP, thereby addressing well-documented gaps in real-world adherence and persistence.²

• This treatment presents an opportunity for health-system specialty pharmacies (HSSPs) to proactively educated and engage patients on PrEP options.

Objectives

To describe the implementation of an HSSP pharmacist-driven workflow designed to identify, educate, and facilitate transition of appropriate oral PrEP patients to long-acting injectable PrEP.